在缺氧条件下，单独及联合使用阿尼芬净和伏立康唑对曲霉属分生孢子和菌丝进行药敏试验。
Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.
作者信息
Perkhofer Susanne, Jost Daniel, Dierich Manfred P, Lass-Flörl Cornelia
机构信息
Department of Hygiene, Microbiology and Social Medicine, Medical University of Innsbruck, Fritz-Pregl Str. 3, A-6020 Innsbruck, Austria.
出版信息
Antimicrob Agents Chemother. 2008 May;52(5):1873-5. doi: 10.1128/AAC.01572-07. Epub 2008 Mar 17.
Abstract
MICs and fractional inhibitory concentrations were evaluated for anidulafungin and voriconazole alone and in combination against conidia and hyphae under hypoxic (1% oxygen-5% CO(2)-94% nitrogen) conditions against 31 Aspergillus isolates. Anidulafungin exhibited excellent activity against conidia and hyphae of Aspergillus spp. The visual reading of the MIC for anidulafungin was optimal under hypoxic conditions.
摘要
在低氧（1%氧气-5%二氧化碳-94%氮气）条件下，对阿尼芬净和伏立康唑单独及联合使用针对31株曲霉菌分离株的分生孢子和菌丝体的最低抑菌浓度（MIC）及最低抑菌浓度分数进行了评估。阿尼芬净对曲霉菌属的分生孢子和菌丝体表现出优异的活性。在低氧条件下，阿尼芬净MIC的肉眼读数最为理想。
相似文献
1
Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.
Antimicrob Agents Chemother. 2008 May;52(5):1873-5. doi: 10.1128/AAC.01572-07. Epub 2008 Mar 17.
2
Effect of protein binding on the activity of voriconazole alone or combined with anidulafungin against Aspergillus spp. using a time-kill methodology.
Rev Esp Quimioter. 2012 Mar;25(1):47-55.
3
In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
Diagn Microbiol Infect Dis. 2012 Jun;73(2):135-7. doi: 10.1016/j.diagmicrobio.2012.02.003.
4
In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.
Antimicrob Agents Chemother. 2013 Feb;57(2):796-803. doi: 10.1128/AAC.00980-12. Epub 2012 Nov 26.
5
In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp.
Antimicrob Agents Chemother. 2012 Aug;56(8):4500-3. doi: 10.1128/AAC.00045-12. Epub 2012 May 21.
6
The effects of antifungal agents to conidial and hyphal forms of Aspergillus fumigatus.
Med Mycol. 2010 Feb;48(1):48-55. doi: 10.3109/13693780802713497.
7
Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Antimicrob Agents Chemother. 2012 Oct;56(10):5180-5. doi: 10.1128/AAC.01111-12. Epub 2012 Jul 23.
8
Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
Antimicrob Agents Chemother. 2008 Jan;52(1):321-8. doi: 10.1128/AAC.00699-07. Epub 2007 Oct 15.
9
Comparison between Aspergillus fumigatus conidia and hyphae susceptibilities to amphotericin B, itraconazole, and voriconazole by use of the mold rapid susceptibility assay.
Med Mycol. 2005 Sep;43(6):525-32. doi: 10.1080/13693780500050796.
10
In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
Antimicrob Agents Chemother. 2005 Aug;49(8):3572-4. doi: 10.1128/AAC.49.8.3572-3574.2005.
引用本文的文献
1
Antifungal Resistance in Non-fumigatus Aspergillus Species.
Mycoses. 2025 Apr;68(4):e70051. doi: 10.1111/myc.70051.
2
Effect of reduced oxygen on the antifungal susceptibility of clinically relevant aspergilli.
Antimicrob Agents Chemother. 2015 Mar;59(3):1806-10. doi: 10.1128/AAC.04204-14. Epub 2014 Dec 29.
3
Susceptibility profiles of amphotericin B and posaconazole against clinically relevant mucorales species under hypoxic conditions.
Antimicrob Agents Chemother. 2015 Feb;59(2):1344-6. doi: 10.1128/AAC.04424-14. Epub 2014 Dec 1.
4
In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.
Antimicrob Agents Chemother. 2013 Feb;57(2):796-803. doi: 10.1128/AAC.00980-12. Epub 2012 Nov 26.
5
Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Antimicrob Agents Chemother. 2012 Oct;56(10):5180-5. doi: 10.1128/AAC.01111-12. Epub 2012 Jul 23.
6
In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp.
Antimicrob Agents Chemother. 2012 Aug;56(8):4500-3. doi: 10.1128/AAC.00045-12. Epub 2012 May 21.
7
Hypoxia and fungal pathogenesis: to air or not to air?
Eukaryot Cell. 2012 May;11(5):560-70. doi: 10.1128/EC.00031-12. Epub 2012 Mar 23.
8
Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.
Mycopathologia. 2012 Apr;173(4):251-7. doi: 10.1007/s11046-011-9507-6. Epub 2011 Dec 4.
9
In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?
Curr Infect Dis Rep. 2010 Nov;12(6):401-8. doi: 10.1007/s11908-010-0134-z.
10
Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.
Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1287-300. doi: 10.1517/17425255.2010.518143.
本文引用的文献
1
Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology.
Med Mycol. 2006 Sep 1;44(Supplement_1):S319-S325. doi: 10.1080/13693780600779401.
2
Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.
J Clin Microbiol. 2007 Jul;45(7):2180-2. doi: 10.1128/JCM.00399-07. Epub 2007 May 2.
3
Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
Antimicrob Agents Chemother. 2007 Feb;51(2):791-3. doi: 10.1128/AAC.01024-06. Epub 2006 Nov 20.
4
Anidulafungin: a novel echinocandin.
Clin Infect Dis. 2006 Jul 15;43(2):215-22. doi: 10.1086/505204. Epub 2006 Jun 9.
5
Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus.
Antimicrob Agents Chemother. 2006 Mar;50(3):868-73. doi: 10.1128/AAC.50.3.868-873.2006.
6
In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
Antimicrob Agents Chemother. 2005 Aug;49(8):3572-4. doi: 10.1128/AAC.49.8.3572-3574.2005.
7
Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
Antimicrob Agents Chemother. 2005 Mar;49(3):1232-5. doi: 10.1128/AAC.49.3.1232-1235.2005.
8
Aspergillus hyphae in infected tissue: evidence of physiologic adaptation and effect on culture recovery.
J Clin Microbiol. 2005 Jan;43(1):382-6. doi: 10.1128/JCM.43.1.382-386.2005.
9
Combination antifungal therapy for invasive aspergillosis.
Clin Infect Dis. 2004 Sep 15;39(6):797-802. doi: 10.1086/423380. Epub 2004 Aug 27.
10
Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida.
J Antimicrob Chemother. 2004 May;53(5):743-9. doi: 10.1093/jac/dkh153. Epub 2004 Mar 24.
Zotero 插件